- Research news
- Open Access
Genome Biology volume 3, Article number: spotlight-20020321-01 (2002)
In the March 19 Proceedings of the National Academy of Sciences, Kashani-Sabet et al. describe the use of plasmid-based ribozymes as functional genomics tools to unravel complex phenotypes, such as cancer metastasis (Proc Natl Acad Sci USA 2002, 99:3878-3883). They reasoned that ribozyme-based gene targeting in mice might overcome experimental problems associated with transgenesis and lethal knockout phenotypes. They tested the use of systemic administration of cationic liposome:DNA complexes (CLDCs) to express hammerhead ribozymes in tumour-bearing mice; they targeted the p65 and p50 subunits of the NF-kappaB transcription factor using expression plasmids based on Epstein-Barr virus and including 35-bp ribozymes. They injected the CLDCs into the bloodstream of mice and noted a reduction in NF-κB proteins in metastatic tumour cells. The ribozymes affected the metastatic spread of melanoma cells; and the ribozymes appear to be more effective than antisense strategies, offering an experimental strategy to dissect complex traits in adult animals.
Proceedings of the National Academy of Sciences, [http://www.pnas.org]
Activators and target genes of Rel/NF-kB transcription factors.
The experimental use of antisense oligonucleotides: a guide for the perplexed.
About this article
Cite this article
Weitzman, J.B. Ribozyme targeting. Genome Biol 3, spotlight-20020321-01 (2002). https://doi.org/10.1186/gb-spotlight-20020321-01
- Melanoma Cell
- Cationic Liposome
- Complex Phenotype
- Metastatic Tumour